Forest Labs’ Drug Proves Effective Against Skin Infections

Two Phase III studies of ceftaroline for the treatment of complicated skin and skin structure infections produced promising data.
 
In both globally conducted, multicenter studies, Forest Laboratories' drug achieved the primary endpoint of noninferiority compared with the combination of vancomycin plus aztreonam, the company said.

Ceftaroline was generally well tolerated.